Publication of Shareholder Letter

Paris (France), Copenhagen (Denmark) Onxeo S.A. (Euronext Paris, Nasdaq Copenhagen: ONXEO), an innovative company specialized in the development of orphan oncology therapeutics, today announced the publication of an Onxeo Shareholder Letter.

This Shareholder Letter provides an update on Onxeo’s achievements in 2016 so far with a special focus on the newest addition to our pipeline, AsiDNATM.

The Shareholder Letter is available on the company’s website in the section Media or Investors/Shareholders.

Download Press Release

Download Shareholder Letter